HOME ·

02256.HK

ABBISKO-B (02256.HK): First patient dosed in Phase I trial of pan-KRAS inhibitor ABSK211, preclinically covering multiple KRAS alterations
Tags：
ABBISKO-B02256.HKClinical Trial
2026-08-31
ABBISKO-B(02256.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 193.47 million, turned into a loss from a profit YoY
Tags：
ABBISKO-B02256.HK
2026-08-25
ABBISKO-B (02256.HK): IND application of oral pan-KRAS inhibitor ABSK211 approved by NMPA
Tags：
ABBISKO-B02256.HKClinical Trial
2026-08-19
ABBISKO-B (02256.HK): Oral Pan-KRAS Inhibitor ABSK211 Cleared by FDA for Phase I Trial in KRAS-Altered Solid Tumours
Tags：
ABBISKO-B02256.HKClinical Trial
2026-07-13
Abbisko(02256.HK): Strategic Cooperation Reached with AstraZeneca to Advance Clinical Study of ABSK043 Combined with Tagrisso for NSCLC Treatment
Tags：
Abbisko02256.HK
2026-07-02
ABBISKO-B(02256.HK): Positive Preliminary Phase II Data of ABSK061 Plus ABSK043 for FGFR2-Positive Advanced Gastric Cancer Released
Tags：
ABBISKO-B02256.HKASCO 2026
2026-06-26
ABBISKO-B(02256.HK): Enters Strategic Research Collaboration and License Agreement with Eli Lilly, Total Potential Deal Value Up to USD1.9 Billion
Tags：
ABBISKO-B02256.HKstrategic cooperation
2026-06-24
Heng Pharmaceutical-B (02256.HK) Presents Novel Combination Modelling Framework for ABSK-011 at PAGE Conference
Tags：
Heng Pharmaceutical-B02256.HK
2026-06-04
ABBISKO-B (02256.HK) plans to issue in total 42.9 million shares by placement, with estimated net proceeds of HKD 517.3 million
Tags：
ABBISKO-B02256.HKNewTimeSpace
2026-04-21